CNTA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Centessa Pharmaceuticals PLC (CNTA) is not a strong buy at the moment for a beginner investor with a long-term focus. While the stock has bullish moving averages and strong analyst support with high price targets, the lack of recent positive news, insider selling, and weak financial performance make it less appealing. The options data also suggests bearish sentiment in the short term. A hold is recommended until more positive catalysts emerge.
The stock shows bullish moving averages (SMA_5 > SMA_20 > SMA_200) and a positive MACD histogram (0.121). RSI is neutral at 55.673, indicating no clear overbought or oversold conditions. Key resistance levels are at 27.308 and 28.146, while support levels are at 24.596 and 23.758.
Strong analyst support with multiple Buy ratings and price targets ranging from $33 to $
Hedge funds are significantly increasing their positions, with a 325.14% increase in buying activity over the last quarter.
Insiders are selling heavily, with a 3778.14% increase in selling activity over the last month.
No recent news or event-driven catalysts to support a bullish case.
Weak financial performance with negative net income (-$54.89M) and EPS (-0.41), despite slight YoY improvements.
In Q3 2025, the company reported no revenue growth (0% YoY), a net income of -$54.89M (up 28.96% YoY), and an EPS of -0.41 (up 10.81% YoY). Gross margin remained at 100%, but the company is still not profitable.
Analysts are bullish on CNTA, with multiple Buy ratings and price targets ranging from $33 to $62. Wolfe Research, Truist, Needham, and Oppenheimer all see significant upside potential, particularly due to the company's lead asset ORX750 and its potential commercialization in 2028.
